V
Vivian I. Franco
Researcher at Wayne State University
Publications - 42
Citations - 2138
Vivian I. Franco is an academic researcher from Wayne State University. The author has contributed to research in topics: Cardiotoxicity & Anthracycline. The author has an hindex of 22, co-authored 42 publications receiving 1851 citations. Previous affiliations of Vivian I. Franco include Roswell Park Cancer Institute & Boston Children's Hospital.
Papers
More filters
Journal ArticleDOI
Anthracycline-associated cardiotoxicity in survivors of childhood cancer.
Barry H. Trachtenberg,David C. Landy,Vivian I. Franco,Jacqueline M. Henkel,Elliot J. Pearson,Tracie L. Miller,Steven E. Lipshultz +6 more
TL;DR: Researchers investigating the use of agents such as angiotensin-converting enzyme (ACE)-inhibitors and beta-blockers to treat anthracycline cardiotoxicity have shown promise, but more data are needed.
Journal ArticleDOI
Treatment-related cardiotoxicity in survivors of childhood cancer
TL;DR: All survivors of childhood cancer are at increased risk of cardiotoxicity, suggesting that survivor screening recommendations for assessment of global risk of premature cardiovascular disease should apply to all survivors.
Journal ArticleDOI
Anthracycline-Induced Cardiotoxicity: A Review of Pathophysiology, Diagnosis, and Treatment
TL;DR: Progress made over the past two decades in understanding the molecular and genetic basis of anthracycline-induced cardiotoxicity is reviewed; detecting and monitoring myocardial dysfunction; using adjunct cardioprotectant therapies; and improvingCardioprotection with agents such as liposomal and pegylated doxorubicin are reviewed.
Journal ArticleDOI
Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children’s Oncology Group Randomized Trial Pediatric Oncology Group 9404
Barbara L. Asselin,Meenakshi Devidas,Lu Chen,Vivian I. Franco,Jeanette Pullen,Michael J. Borowitz,Robert E. Hutchison,Yaddanapudi Ravindranath,Saro H. Armenian,Bruce M. Camitta,Steven E. Lipshultz +10 more
TL;DR: In this article, the authors evaluated the oncologic efficacy, cardioprotective effectiveness, and safety of dexrazoxane added to chemotherapy that included a cumulative doxorubicin dose of 360 mg/m2 to treat children and adolescents with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL) or lymphblastic non-Hodgkin lymphoma (L-NHL).
Journal ArticleDOI
Cardiotoxicity in childhood cancer survivors: strategies for prevention and management.
TL;DR: Dexrazoxane is the only known agent to date, that is associated with less cardiac dysfunction, without reducing the oncologic efficacy of the anthracycline doxorubicin in children, which is essential to investigate new approaches to improving the safety of cancer treatments.